Artelo Biosciences, Inc. (ARTL, Financial), a biopharmaceutical company focused on lipid signaling pathway therapies, experienced a 5.45% drop in its stock price. The shares are currently priced at $1.04 with a trading volume of 17,291 shares and a turnover rate of 0.54%. The company's recent financial report shows zero revenue, a net loss of $1.13 million, and an earnings per share (EPS) of -$0.35. The price-to-earnings (P/E) ratio stands at -0.37.
Despite the financial results, all three rating agencies covering Artelo Biosciences have recommended a buy, with no hold or sell ratings. This is noteworthy given the overall 0.86% growth in the biotechnology sector, where Artelo operates.
In the biotech sector, other stocks such as Neurosense Therapeutics Ltd and Protagenic Therapeutics Inc have shown significant gains. Meanwhile, companies like Cyclerion Therapeutics, Inc., Outlook Therapeutics, Inc., and Tc Biopharm (Holdings) Plc have been particularly active, with high turnover rates of 988.60%, 233.34%, and 33.80% respectively. Stocks with notable price fluctuations include Neurosense Therapeutics Ltd, Silexion Therapeutics Corp, and Protagenic Therapeutics Inc, showing amplitudes of 86.60%, 79.26%, and 78.75% respectively.
Artelo Biosciences is committed to developing therapies targeting the endocannabinoid system, a biochemical communication network in the body. The company is focused on discovering, licensing, developing, and commercializing treatments that modulate this system. Their flagship project aims to provide proprietary cannabinoid-based therapies for rare and orphan diseases.
